{
  "ticker": "LLY",
  "timestamp": "2025-12-01T08:36:58.555045",
  "analysis_date": "2025-06-11",
  "historical_mode": true,
  "summary": {
    "recommendations": {
      "technical": "BUY",
      "news": "BUY",
      "fundamental": "HOLD",
      "macro": "HOLD"
    },
    "valid_recommendations": {
      "technical": "BUY",
      "news": "BUY",
      "fundamental": "HOLD",
      "macro": "HOLD"
    },
    "confidence_levels": {
      "technical": "Medium",
      "news": "Medium",
      "fundamental": "Low",
      "macro": "Low"
    },
    "bull_signal_count": 32,
    "bear_signal_count": 14,
    "bull_rec_count": 2,
    "bear_rec_count": 0,
    "hold_rec_count": 2,
    "undetermined_count": 0,
    "analyst_count": 4,
    "valid_analyst_count": 4,
    "net_sentiment": "BULLISH"
  },
  "analyst_summaries": {
    "technical": "TECHNICAL: Uptrend confirmed, RSI 14 \u2192 BUY (Medium)",
    "news": "NEWS: Bullish sentiment (66 articles) \u2192 BUY (Medium)",
    "fundamental": "FUNDAMENTAL: Mixed fundamentals \u2192 HOLD (Low)",
    "macro": "MACRO: Risk-on environment, VIX 17.3 \u2192 HOLD (Low)"
  },
  "full_analyst_reports": {
    "technical": "[TECHNICAL] *** HISTORICAL MODE: Analyzing as of 2025-06-11 ***\n\n======================================================================\nTECHNICAL ANALYSIS: LLY\nAnalysis Period: 7 days\n*** HISTORICAL MODE: As of 2025-06-11 ***\nTimestamp: 2025-12-01 08:35:33\n======================================================================\n\n[TECHNICAL] Fetching 7-day price data for LLY...\n[TECHNICAL] \u2713 Historical: 51 days ending 2025-06-11\n[TECHNICAL]   Date range: 2025-03-31 to 2025-06-11\n[TECHNICAL] \u2713 Retrieved 51 days of data\n[TECHNICAL] Calculating technical indicators...\n[TECHNICAL] \u2713 Indicators calculated\n[TECHNICAL] Identifying support/resistance levels...\n[TECHNICAL] \u2713 Support: $706.41, Resistance: $817.72\n[TECHNICAL] Formatting technical summary...\n[TECHNICAL] Generating analysis with gpt-4o-mini...\n[TECHNICAL] \u274c LLM error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n[TECHNICAL] Creating fallback analysis...\n\n[TECHNICAL] \u2713 Analysis complete in 18.71s\n======================================================================\n\n## Technical Analysis\n*Generated using fallback analysis (LLM unavailable)*\n\n\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-11 \u26a0\ufe0f**\nAll data below is historical, ending on 2025-06-11.\nDo NOT reference any price movements or events after this date.\n\n# Technical Analysis Data for LLY\n\n**Analysis Period:** 7 days (Data: 51 days available)\n**Date:** 2025-06-11\n\n## Price Action\n- **Current Price:** $805.65\n- **Period Change:** +7.70%\n- **Day's Range:** $802.09 - $817.72\n- **Volume:** 3,125,400\n- **Volume Assessment:** Normal levels\n\n## Momentum Indicators\n- **RSI(14):** 85.4 \u2192 **OVERBOUGHT** (Potential pullback) \u26a0\ufe0f\n- **MACD:** 3.997 | Signal: -6.630 | Histogram: 10.627\n  \u2192 Bullish momentum \u2713\n- **Stochastic:** %K=89.2, %D=93.3\n  \u2192 Overbought territory\n\n## Moving Average Analysis\n- **SMA_5:** $782.14 (Above \u2713)\n- **EMA_10:** $769.90 (Above \u2713)\n- **SMA_20:** $744.91 (Above \u2713)\n- **SMA_50:** $770.33 (Above \u2713)\n\n**Trend:** Strong uptrend (price above all MAs) \u2713\n\n## Volatility & Range\n- **Bollinger Bands:** $688.22 < $805.65 < $801.61\n  \u2192 Near upper band (Resistance zone) \u26a0\ufe0f\n  \u2192 Wide bands (15.2%) - High volatility\n- **ATR:** $16.85 (2.09% of price)\n  \u2192 Normal volatility\n\n## Support & Resistance\n- **Key Resistance:** $817.72\n- **Secondary Resistance:** $805.67\n- **Key Support:** $706.41\n- **Secondary Support:** $708.16\n\n- **Distance to Resistance:** +1.5%\n- **Distance to Support:** +14.0%\n\n## Potential Trade Setup\n- **Setup Type:** LONG\n- **Entry:** $805.65\n- **Stop Loss:** $780.38 (Risk: $25.27)\n- **Target:** $817.72 (Reward: $12.07)\n- **Risk/Reward Ratio:** 0.48:1\n  \u2192 Poor risk/reward \u26a0\ufe0f\n\n\n---\n\n## Automated Assessment\n\n**Signals Detected:** 2 bullish, 0 bearish\n**Reasoning:** Multiple bullish signals: Strong uptrend, Price above MAs\n\nRECOMMENDATION: BUY - Confidence: Medium\n\n",
    "news": "[NEWS] *** HISTORICAL MODE: Analyzing as of 2025-06-11 ***\n\n======================================================================\nNEWS & SENTIMENT ANALYSIS: LLY\n*** HISTORICAL MODE: As of 2025-06-11 ***\nPeriod: Last 7 days | Sources: ['yahoo', 'finnhub']\nTimestamp: 2025-12-01 08:35:54\n======================================================================\n\n[NEWS] \ud83d\udd27 Fetching Yahoo Finance news...\n[NEWS] \u26a0\ufe0f Yahoo Finance has limited historical news support\n[NEWS] \u2713 Yahoo Finance: 0 articles\n[NEWS] \ud83d\udd27 Fetching Finnhub news...\n[NEWS] Finnhub: Fetching news from 2025-06-04 to 2025-06-11\n[NEWS] \u2713 Finnhub: 66 articles\n[NEWS] \ud83d\udccb Enhancing 66 articles with background context\n[NEWS] \u26a0\ufe0f Date 2025-06-11 is past LLM knowledge cutoff (2024-01-01)\n[NEWS] \u26a0\ufe0f Skipping LLM context to prevent hallucination\n[NEWS] Analyzing with gpt-4o-mini...\n[NEWS] \u2713 Analysis complete (2701 chars)\n\n[NEWS] \u2713 Analysis complete in 19.10s\n======================================================================\n\n# News & Sentiment Analysis: LLY\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-11 \u26a0\ufe0f**\n**Analysis Period:** Last 7 Days\n**Date:** 2025-12-01 08:35\n\n======================================================================\n\n## Yahoo Finance News (7 Days before 2025-06-11)\n\nNo news found in the specified period\n(Historical mode: news before 2025-06-11)\n## Finnhub News (2025-06-04 to 2025-06-11)\n\n**Found 66 articles**\n\n1. **Eli Lilly (NYSE:LLY) Collaborates With Juvena To Enhance Muscle Health Through AI Technology**\n   - Source: Yahoo\n   - Published: today\n   - Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore AI-driven drug candidates...\n\n2. **Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel**\n   - Source: Yahoo\n   - Published: today\n   - Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Don...\n\n3. **Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?**\n   - Source: Yahoo\n   - Published: today\n   - LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition....\n\n4. **Eli Lilly telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to**\n   - Source: Yahoo\n   - Published: today\n   - Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales....\n\n5. **Juvena Therapeutics and Eli Lilly and Company Enter Research Collaboration Focused on Muscle Health**\n   - Source: Finnhub\n   - Published: today\n   - Juvena Therapeutics, Inc. announced it has entered a global licensing and multi-target research collaboration with Eli Lilly and Company to discover, ...\n\n6. **Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple**\n   - Source: Finnhub\n   - Published: today\n   - Denmark's Novo Nordisk ispartnering with biotech company Deep Apple Therapeutics in adeal worth up to $812 million to develop drugs forcardiometabolic...\n\n7. **Should You Buy Eli Lilly Stock Before June 22?**\n   - Source: Yahoo\n   - Published: today\n   - Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month.  Eli Lilly (NYSE: LLY) stock hasn't been doing too well this ...\n\n8. **The cheap fat jabs sending big pharma into a frenzy**\n   - Source: Yahoo\n   - Published: today\n   - For many Americans who tuned in to watch the Super Bowl earlier this year, it was a surprise to find themselves fat-shamed during the ad break....\n\n\n======================================================================\n\n## News & Sentiment Summary\nEli Lilly (LLY) has recently announced a significant collaboration with Juvena Therapeutics focused on enhancing muscle health through AI-driven drug candidates. This news comes amidst ongoing discussions about the company's competitive positioning in the obesity treatment market, particularly with its products Mounjaro and Zepbound. The overall sentiment in the market appears to be cautiously optimistic, with attention on upcoming data presentations expected to influence stock performance.\n\n## Key Headlines\n1. **Eli Lilly Collaborates With Juvena To Enhance Muscle Health Through AI Technology**  \n   - **Impact Assessment:** High potential price impact due to strategic collaboration aimed at innovation in drug development.\n   \n2. **Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?**  \n   - **Impact Assessment:** Medium potential impact as it addresses competitive pressures and sales expectations, key for investor confidence.\n   \n3. **Eli Lilly Telehealth Partners Continue to Sell Compounded GLP-1 Weight-Loss Drugs**  \n   - **Impact Assessment:** Medium impact, as this situation could complicate Lilly's market position despite existing agreements.\n\n4. **Novo Signs $812 Million Weight-Loss Drug License Deal With US Biotech Deep Apple**  \n   - **Impact Assessment:** Medium impact due to competitive landscape shifts that could affect Lilly's market share.\n\n5. **Should You Buy Eli Lilly Stock Before June 22?**  \n   - **Impact Assessment:** Medium, as it prompts investor speculation ahead of important data presentations.\n\n## Sentiment Assessment\n- **Overall Sentiment:** Bullish\n- **Sentiment Trend:** Improving\n- **News Volume:** High\n\n## Catalysts Identified\n**Bullish Catalysts:**\n- Collaboration with Juvena Therapeutics for AI-driven drug development.\n- Anticipation of data presentations on GLP-1 drugs which could positively influence stock sentiment.\n\n**Bearish Catalysts:**\n- Continued competition in the obesity drug market, particularly challenges from Novo Nordisk and compounded GLP-1 sales.\n\n**Upcoming Events:**\n- Data presentations on multiple GLP-1 drugs expected on June 22.\n\n## Trading Implications\nGiven the recent collaboration and the upcoming data presentations, there is a bullish sentiment surrounding LLY. The collaboration could enhance its product portfolio and market position, while the data presentations present an opportunity for positive price movement. However, competition remains a significant concern that could temper gains. Investors should consider positioning for potential upside ahead of the data release while being mindful of competitive risks.\n\nRECOMMENDATION: BUY - Confidence: Medium\n",
    "fundamental": "[FUNDAMENTALS] *** HISTORICAL MODE: Analyzing as of 2025-06-11 ***\n\n======================================================================\nFUNDAMENTAL ANALYSIS: LLY\n*** HISTORICAL MODE: As of 2025-06-11 ***\nTimestamp: 2025-12-01 08:36:16\n======================================================================\n\n[FUNDAMENTALS] Fetching comprehensive data for LLY...\n[FUNDAMENTALS] \u2713 Comprehensive data retrieved\n[FUNDAMENTALS] Calculating historical metrics for 2025-06-11...\n[FUNDAMENTALS] \u2713 Historical metrics calculated: 4\n[FUNDAMENTALS]   - Price: $805.65\n[FUNDAMENTALS]   - P/E: 88.59\n[FUNDAMENTALS]   - P/B: 45.74\n[FUNDAMENTALS]   - Current Ratio: 1.37\n[FUNDAMENTALS] Analyzing earnings history...\n[FUNDAMENTALS] Filtering earnings to before 2025-06-11\n[FUNDAMENTALS] \u2713 Earnings analysis complete (3/4 beats)\n[FUNDAMENTALS] Fetching SEC 10-K filing data...\n[FUNDAMENTALS] Generating analysis with gpt-4o-mini...\n[FUNDAMENTALS] \u274c LLM error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n\n[FUNDAMENTALS] \u2713 Analysis complete in 19.48s\n======================================================================\n\n## Fundamental Analysis Summary\n*Generated using fallback analysis (LLM unavailable)*\n\n\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-11 \u26a0\ufe0f**\nMetrics marked \"N/A\" could not be calculated historically - ignore them in your analysis.\nOnly analyze metrics with actual values.\n\n# Fundamental Data for LLY\n\n## Company Information\n- **Name:** Eli Lilly and Company\n- **Sector:** Healthcare\n- **Industry:** Drug Manufacturers - General\n\n## Current Price\n- **Price:** $805.65\n- **52-Week High:** $1111.99\n- **52-Week Low:** $623.78\n\n## Valuation Metrics\n- **Market Cap:** $964.11B\n- **Enterprise Value:** $995.68B\n- **Trailing P/E:** 88.59\n- **Forward P/E:** N/A (historical - forward-looking)\n- **PEG Ratio:** N/A (historical)\n- **Price/Book:** 45.74\n- **Price/Sales:** 16.23\n- **EV/Revenue:** 16.76\n- **EV/EBITDA:** 34.66\n\n## Growth Metrics\n- **Revenue Growth:** 53.9%\n- **Earnings Growth:** 480.4%\n- **Quarterly Revenue Growth:** N/A\n- **Quarterly Earnings Growth:** N/A\n\n## Profitability\n- **Profit Margin:** 31.0%\n- **Operating Margin:** 48.3%\n- **Gross Margin:** 83.0%\n- **ROE:** 96.5%\n- **ROA:** 17.6%\n\n## Financial Health\n- **Current Ratio:** 1.37\n- **Quick Ratio:** 0.72\n- **Debt/Equity:** 178.52\n- **Total Cash:** $9.91B\n- **Total Debt:** $42.58B\n- **Free Cash Flow:** $1.40B\n\n## Analyst Opinions\n- **Recommendation:** BUY\n- **Number of Analysts:** 27\n- **Target (Mean):** $1024.00\n- **Target (High):** $1500.00\n- **Target (Low):** $770.00\n- **Implied Upside:** -4.8%\n\n## Earnings History (Last 4 Quarters)\n- Unknown: Actual $5.32 vs Est $5.07 (+5.0%) \u2713 Beat\n- Unknown: Actual $3.34 vs Est $3.54 (-5.7%) \u2717 Miss\n- Unknown: Actual $6.31 vs Est $5.59 (+12.9%) \u2713 Beat\n- Unknown: Actual $7.02 vs Est $5.89 (+19.2%) \u2713 Beat\n\n**Summary:** Beat Rate: 75%, Trend: Declining, Quality: Strong\n\n\n\nRECOMMENDATION: HOLD - Confidence: Low\n\n",
    "macro": "[MACRO] *** HISTORICAL MODE: Analyzing as of 2025-06-11 ***\n\n======================================================================\nMACRO ECONOMIC ANALYSIS\nPeriod: 7 days | Sector: All\n*** HISTORICAL MODE: As of 2025-06-11 ***\nTimestamp: 2025-12-01 08:36:38\n======================================================================\n\n[MACRO] Starting iterative analysis...\n[MACRO] Iteration 1/10\n[MACRO] \u274c Error in iterative analysis: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n[MACRO] Running fallback mode (no LLM)\n[MACRO] \ud83d\udd27 Tool: get_market_indicators (days=7)\n[MACRO] \u2713 Fetched 6/6 indicators\n[MACRO] \ud83d\udd27 Tool: get_sector_performance (days=7)\n[MACRO] \u2713 Analyzed 9/9 sectors\n[MACRO] \ud83d\udd27 Tool: get_economic_indicators (days=7)\n[MACRO] \u2713 Economic indicators retrieved\n[MACRO] \ud83d\udd27 Tool: get_market_breadth (days=7)\n[MACRO] \u2713 Breadth analysis complete\n\n[MACRO] \u2713 Complete in 20.20s\n======================================================================\n\n# Macro Analysis (7-Day)\n*Generated: 2025-12-01 08:36*\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-11**\n\n## Market Indicators (7-Day Analysis)\n\n**\u26a0\ufe0f Historical Data as of: 2025-06-11**\n\n**S&P 500:** 6022.24 | +2.27% | Vol: 7.2% | Strong Uptrend\n**Dow Jones:** 42865.77 | +1.82% | Vol: 6.0% | Strong Uptrend\n**NASDAQ:** 19615.88 | +2.70% | Vol: 10.1% | Strong Uptrend\n**VIX (Volatility):** 17.26 | -10.62% | Vol: 61.4% | Strong Downtrend\n**10-Year Treasury:** 4.41 | -1.45% | Vol: 21.6% | Sideways\n**Russell 2000:** 2148.23 | +3.89% | Vol: 11.8% | Strong Uptrend\n\n## Sector Performance (7-Day)\n\n**\u26a0\ufe0f Historical Data as of: 2025-06-11**\n\n**Leaders:**\n- Energy: +5.68% (Momentum: +3.86%)\n- Technology: +3.94% (Momentum: +2.43%)\n- Healthcare: +3.25% (Momentum: +2.03%)\n\n**Laggards:**\n- Utilities: +0.47% (Momentum: -0.52%)\n- Consumer Discretionary: -0.07% (Momentum: +0.85%)\n- Consumer Staples: -0.37% (Momentum: -0.64%)\n\n**Rotation:** Mixed (+1.46% vs +1.12%) \u2192 NEUTRAL\n\n## Economic Indicators (7-Day)\n\n**\u26a0\ufe0f Historical Data as of: 2025-06-11**\n\n**Dollar Index:** $98.63 | -1.25% \u2192 Neutral\n**Gold:** $3321.30 | +0.84% \u2192 Neutral\n**Crude Oil:** $68.15 | +10.20% \u2192 Neutral\n**Bitcoin:** $108686.62 | +0.82% \u2192 Neutral\n**High Yield Bonds:** $77.60 | +0.64% \u2192 Neutral\n**20Y Treasury:** $84.57 | +1.29% \u2192 Neutral\n\n## Market Breadth (7-Day)\n\n**\u26a0\ufe0f Historical Data as of: 2025-06-11**\n\n**Small vs Large Cap:**\n- S&P 500: +2.27%\n- Russell 2000: +3.89%\n- Spread: +1.62%\n\n**Signal:** Small caps outperforming \u2192 RISK-ON \u2713\n\n\n## Assessment\n\u26a0\ufe0f **Limited Analysis** - LLM unavailable, showing raw data only\n\nRECOMMENDATION: NEUTRAL - Confidence: Low\n\n"
  },
  "bull_evidence": [
    {
      "source": "technical",
      "signal": "\u2192 Bullish momentum \u2713",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "technical",
      "signal": "**Reasoning:** Multiple bullish signals: Strong uptrend, Price above MAs",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "technical",
      "signal": "[TECHNICAL] \u2713 Support: $706",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "## Momentum Indicators",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "**Trend:** Strong uptrend (price above all MAs) \u2713",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Key Support:** $706",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Secondary Support:** $708",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Distance to Support:** +14",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "RECOMMENDATION: BUY - Confidence: Medium",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "[NEWS] \u26a0\ufe0f Yahoo Finance has limited historical news support",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Should You Buy Eli Lilly Stock Before June 22?**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Should You Buy Eli Lilly Stock Before June 22?**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- **Overall Sentiment:** Bullish",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- **Sentiment Trend:** Improving",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Bullish Catalysts:**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- Anticipation of data presentations on GLP-1 drugs which could positively influence stock sentiment",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "Given the recent collaboration and the upcoming data presentations, there is a bullish sentiment surrounding LLY",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "The collaboration could enhance its product portfolio and market position, while the data presentations present an opportunity for positive price movement",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "RECOMMENDATION: BUY - Confidence: Medium",
      "strength": 1,
      "keywords_matched": 1
    }
  ],
  "bear_evidence": [
    {
      "source": "technical",
      "signal": "41, Resistance: $817",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "4 \u2192 **OVERBOUGHT** (Potential pullback) \u26a0\ufe0f",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "\u2192 Overbought territory",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "\u2192 Near upper band (Resistance zone) \u26a0\ufe0f",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Key Resistance:** $817",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Secondary Resistance:** $805",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Distance to Resistance:** +1",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Risk/Reward Ratio:** 0",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "\u2192 Poor risk/reward \u26a0\ufe0f",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Eli Lilly telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Eli Lilly Telehealth Partners Continue to Sell Compounded GLP-1 Weight-Loss Drugs**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Bearish Catalysts:**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "However, competition remains a significant concern that could temper gains",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "macro",
      "signal": "**Russell 2000:** 2148",
      "strength": 1,
      "keywords_matched": 1
    }
  ],
  "key_conflicts": [
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "fundamental",
        "technical"
      ],
      "positions": {
        "fundamental": "HOLD",
        "technical": "BUY"
      },
      "description": "fundamental says HOLD while technical says BUY"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "fundamental",
        "news"
      ],
      "positions": {
        "fundamental": "HOLD",
        "news": "BUY"
      },
      "description": "fundamental says HOLD while news says BUY"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "macro",
        "technical"
      ],
      "positions": {
        "macro": "HOLD",
        "technical": "BUY"
      },
      "description": "macro says HOLD while technical says BUY"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "macro",
        "news"
      ],
      "positions": {
        "macro": "HOLD",
        "news": "BUY"
      },
      "description": "macro says HOLD while news says BUY"
    }
  ],
  "consensus_points": [
    {
      "type": "partial_consensus",
      "recommendation": "BUY",
      "count": 2,
      "analysts": [
        "technical",
        "news"
      ],
      "description": "Partial consensus: technical and news both say BUY"
    },
    {
      "type": "partial_consensus",
      "recommendation": "HOLD",
      "count": 2,
      "analysts": [
        "fundamental",
        "macro"
      ],
      "description": "Partial consensus: fundamental and macro both say HOLD"
    }
  ],
  "research_priorities": [
    {
      "priority": "URGENT",
      "focus": "time_sensitive_event",
      "description": "Upcoming catalyst detected",
      "signal": "Given the recent collaboration and the upcoming data presentations, there is a bullish sentiment surrounding LLY",
      "source": "news",
      "action": "Research before event occurs"
    }
  ],
  "analyst_reports_summary": {
    "technical": {
      "recommendation": "BUY",
      "confidence": "Medium",
      "report_length": 3125,
      "has_data": true,
      "completed_successfully": true
    },
    "news": {
      "recommendation": "BUY",
      "confidence": "Medium",
      "report_length": 6373,
      "has_data": true,
      "completed_successfully": true
    },
    "fundamental": {
      "recommendation": "HOLD",
      "confidence": "Low",
      "report_length": 3232,
      "has_data": true,
      "completed_successfully": true
    },
    "macro": {
      "recommendation": "HOLD",
      "confidence": "Low",
      "report_length": 2874,
      "has_data": true,
      "completed_successfully": true
    }
  },
  "data_quality": {
    "status": "COMPLETE",
    "total_analysts": 4,
    "valid_analysts": 4,
    "failed_analysts": 0,
    "failed_list": [],
    "note": null
  },
  "llm_synthesis": "Synthesis error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
  "synthesis_direction": "UNDETERMINED",
  "synthesis_confidence": "N/A"
}